Skip to main content

Table 3 Treatment Response on First Daratumumab-Based Regimen

From: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study

 

All patients

Frontline daratumumab patients

Daratumumab initiated in 2 L

Daratumumab initiated in 3 L+

N = 299

N = 26

N = 66

N = 207

Best response achieved per IMWG criteria1, n (%)

 Stringent complete response

16 (5.4)

5 (19.2)

6 (9.1)

5 (2.4)

 Complete response

25 (8.4)

4 (15.4)

4 (6.1)

17 (8.2)

 Very good partial response

99 (33.1)

10 (38.5)

28 (42.4)

61 (29.5)

 Partial response

71 (23.7)

7 (26.9)

14 (21.2)

50 (24.2)

 Minimal response

4 (1.3)

0 (0.0)

2 (3.0)

2 (1.0)

 Stable disease

38 (12.7)

0 (0.0)

5 (7.6)

33 (15.9)

 Progressive disease

43 (14.4)

0 (0.0)

7 (10.6)

36 (17.4)

 Clinical relapse

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Other

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Unknown/not available

3 (1.0)

0 (0.0)

0 (0.0)

3 (1.4)

Patients with known response rate, n (%)

296 (99.0)

26 (100.0)

66 (100.0)

204 (98.6)

 Overall response rate2, n (%)

211 (71.3)

26 (100.0)

52 (78.8)

133 (65.2)

 Very good partial response or better, n (%)

140 (47.3)

19 (73.1)

38 (57.6)

83 (40.7)

 Months from regimen start to best response date, mean ± SD [median]

4.8 ± 5.7 [2.8]

3.7 ± 3.0 [2.9]

5.1 ± 4.9 [3.3]

4.8 ± 6.1 [2.8]

  1. Abbreviations: 2 L: second-line; 3 L: third-line; IMWG: International Myeloma Working Group; SD: standard deviation
  2. Notes
  3. [1] Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug;17 [15]:e328-e346
  4. [2] Overall response rate defined as partial response or better among patients with known response rate